Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

officer and head of R&D, who will discuss our development programs, and Dan Appel, chief financial officer, who will review the financials. Following management's prepared remarks, we will open up the call to questions. Before we begin, I would like to remind you the comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results that differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q. I'd now like to turn the call over to Chris Anzalone, President and CEO of the company. Chris. Thanks, Vince. Good afternoon, everyone, and thank you for joining us today. Before we begin, I'd like to announce that this will be Bruce Gibbons' final earnings call. He's been a valuable member of the Arrowhead team for almost 15 years. He will continue to help Arrowhead as a trusted advisor, but now that Redemplo has received its first FDA approval, he will be stepping back from day-to-day operational responsibilities, and hopefully he can finally enjoy his time in retirement, or in his re-retirement, which is probably more accurate. His contributions to Arrowhead's success, both current and future, have been critical, and we owe him a heartfelt thank you. Later in the call, you will hear from Bruce, who will discuss the redemptive FDA approval when she came back to Arrowhead and out ...